Antibody to a molecularly-defined antigen confined to a tumour cell surface.
about
Adoptive T-cell therapy for LeukemiaImmunotherapy: on the edge between experimental and clinical oncology.Dynamic studies of lymphocytes labelled with indium-111 during and after treatment with monoclonal anti-idiotype antibody in advanced B cell lymphomaRole of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphomaTowards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes.Idiotype vaccines in the treatment of B-cell non-Hodgkin's lymphoma.Mechanisms of tumour cell escape encountered in treating lymphocytic leukaemia with anti-idiotypic antibodyAntibody-induced changes in levels of cyclic adenosine monophosphate in leukaemic lymphocytes.Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.The monoclonality of human B-cell lymphomas.Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens.Mutant lines of guinea pig L2C leukemia. I. Deletion of Ia alloantigens is associated with a loss in immunogenicity of tumor-associated transplantation antigensAnti-idiotype sera raised against surface immunoglobulin of human neoplastic lymphocytesTherapeutic lymphoma vaccines: importance of T-cell immunity.BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.New approaches to the treatment of follicular lymphoma.Therapeutic vaccine for lymphoma.Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.Prospects for the treatment of B cell tumors using idiotypic vaccination.Three major uncertainties in the antibody therapy of cancer.The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sitesAntigen Discovery and Therapeutic Targeting in Hematologic Malignancies.Therapeutic strategies for B cell malignancies involving idiotype-anti-idiotype interactions.Anti-idiotypic antibodies and disease.T lymphocyte stimulation by hapten-conjugated macrophages: a model system for the study of immunocompetent cell interactions.Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis.Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfacesDevelopment of vaccine strategies for the treatment of B-cell malignancies.Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin.Lymphomas can develop from B cells chronically helped by idiotype-specific T cellsExtracellular idiotypic immunoglobulin arising from human leukemic B lymphocytesConsumption of monoclonal anti-idiotypic antibody by neoplastic B lymphocytes: a guide for immunotherapy.Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.Discussion paper: loss of antigenicity associated with deletion of Ia alloantigens in a mutant line of guinea pig L2C leukemia.Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses
P2860
Q27006934-0D8EDB12-BCA1-4AF5-AFA2-09E0281201BDQ34172095-90D30234-A5DD-4D37-8064-6A0D8486C14BQ34553568-86598068-D32D-4F2F-871A-0C0AACB3ED2DQ34734310-35FB39A6-56B0-4608-9F1B-1CDAFDABD66DQ35114545-83ABD287-CD15-4E97-9400-964225BB241EQ35144751-C97A96DC-38C4-4A30-AD39-CAFF833B4E1AQ35740264-A4374F67-A55D-492E-A6AF-A2BD37FEA060Q35991384-24390142-C3E1-4330-A20C-0B395CBEED9DQ36043079-341AB308-75C7-4D0F-8F88-6D0DE83497BFQ36312922-82B88AA9-9951-455E-B9C5-BE10F50C7F2CQ36335226-46281BC7-8CA9-452B-AE35-BD137DBE8268Q36350351-F6990293-B078-448A-BD5E-9B05F2347D36Q36359353-8EF74EF8-2D14-4A70-B6DE-DCF60F0F133BQ36359921-178ABADD-1BE0-4248-AE02-F5C76DDFEC5EQ36530231-55DEE4EC-6A22-4407-A877-BBCB6F7F24B6Q36675461-94EE1640-9738-4B4E-9AE8-68FB850BBEF3Q36704163-6DB784A9-2D70-4058-BD74-6FE3DB12462AQ36746586-00C471D6-B8B7-4389-9927-EFCD6AF0AC79Q37142202-78BA2F3C-05A1-4CCD-B32E-C2C7F862D7A9Q38246920-086665DB-B208-4F68-84FE-EC8BE3C015A3Q38255786-97B29E7F-D2D0-40F9-8561-1FAD0E22CCC1Q38694283-C176754D-AFC5-4399-87B1-D875B60CD644Q39243052-84455253-0263-48F2-B2C8-35F128D85FB3Q39706084-F10CEABA-2A2F-4E78-B41F-6D5B4DE0391CQ39743633-960689D4-F2D6-45A8-9E8C-4A181B58CF1EQ39802469-1915CFD0-2CE5-49D4-AE89-733141727B62Q40568230-A050237C-58FA-4CF5-8D99-8028AA161BAFQ40795774-30E3F561-6B0C-4509-89BE-50099279D432Q41481622-C8F231F4-1878-4F55-92CC-2BEF61F10502Q41669410-0452451D-328C-4C95-AB9F-525306D45569Q41961674-31B6F64C-A1BE-477B-9F2A-79BDC75E8BCAQ41982582-3D36497B-46B7-4213-A7EE-ACC68AE31B5CQ42020504-54026512-69A2-4606-BD27-0B937987FD62Q42033251-D871C247-3767-4CBE-AB7A-4CD0675D108AQ46031680-834F12FD-6D2F-42AD-9167-EE25C6E8F83EQ46397017-E5766F71-9D23-46CA-8909-2CFFC9B94BAAQ49935482-98BBEC89-4126-4F9B-9337-F85B3EC48CA6Q58001062-E6EEBA4C-773B-48BD-BB0E-D5D238A5E6D6
P2860
Antibody to a molecularly-defined antigen confined to a tumour cell surface.
description
1975 nî lūn-bûn
@nan
1975年の論文
@ja
1975年学术文章
@wuu
1975年学术文章
@zh-cn
1975年学术文章
@zh-hans
1975年学术文章
@zh-my
1975年学术文章
@zh-sg
1975年學術文章
@yue
1975年學術文章
@zh
1975年學術文章
@zh-hant
name
Antibody to a molecularly-defined antigen confined to a tumour cell surface.
@en
Antibody to a molecularly-defined antigen confined to a tumour cell surface.
@nl
type
label
Antibody to a molecularly-defined antigen confined to a tumour cell surface.
@en
Antibody to a molecularly-defined antigen confined to a tumour cell surface.
@nl
prefLabel
Antibody to a molecularly-defined antigen confined to a tumour cell surface.
@en
Antibody to a molecularly-defined antigen confined to a tumour cell surface.
@nl
P356
P1433
P1476
Antibody to a molecularly-defined antigen confined to a tumour cell surface.
@en
P2093
Stevenson FK
Stevenson GT
P2888
P304
P356
10.1038/254714A0
P407
P577
1975-04-01T00:00:00Z
P6179
1005419798